Nektar Therapeutics NKTR Transaction Costs And Net Working Capital Adjustment For Sale Of Huntsville Manufacturing Facility Included In Accounts Payable And Accrued Expense
Transaction Costs And Net Working Capital Adjustment For Sale Of Huntsville Manufacturing Facility Included In Accounts Payable And Accrued Expense at other companies
Other financials
Where this comes from
Reported directly by Nektar Therapeutics in its filing.
Tagged under the XBRL concept nktr:TransactionCostsAndNetWorkingCapitalAdjustmentForSaleOfHuntsvilleManufacturingFacilityIncludedInAccountsPayableAndAccruedExpense.
The official record: Nektar Therapeutics’s 10-K, filed March 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nektar Therapeutics's transaction costs and net working capital adjustment for sale of huntsville manufacturing facility included in accounts payable and accrued expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nektar Therapeutics's transaction costs and net working capital adjustment for sale of huntsville manufacturing facility included in accounts payable and accrued expense?
- Nektar Therapeutics (NKTR) reported transaction costs and net working capital adjustment for sale of huntsville manufacturing facility included in accounts payable and accrued expense of $0 in Q4 2025.
- How has Nektar Therapeutics's transaction costs and net working capital adjustment for sale of huntsville manufacturing facility included in accounts payable and accrued expense changed year-over-year?
- Nektar Therapeutics's transaction costs and net working capital adjustment for sale of huntsville manufacturing facility included in accounts payable and accrued expense decreased by 100.0% year-over-year, from $174.25K to $0.
- What does transaction costs and net working capital adjustment for sale of huntsville manufacturing facility included in accounts payable and accrued expense mean?
- This metric captures the impact of transaction-related expenses and post-closing working capital adjustments associated with the sale of a business unit or facility. It reconciles the difference between the initial agreed-upon sale price and the final cash proceeds received after accounting for liabilities and operational adjustments. Monitoring this helps investors understand the true net economic benefit realized from divestiture activities.